IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Oral Viscous Sucralfate Gel for Post-procedural Treatment of Barrett's Esophagus

Author(s):  Zur Eyal

Issue:  Sep/Oct 2019 - Volume 23, Number 5
View All Articles in Issue

Note:  Electronic version includes supplemental material.

Abstract:  Barrett's esophagus refers to an abnormal change in the cells of the lower portion of the esophagus. It is characterized by the replacement of the normal stratified squamous epithelium lining of the esophagus by columnar epithelium cells which are usually found lower in the gastrointestinal tract. The medical significance of this pathology is approximately 0.5% risk to develop esophageal adenocarcinoma (per patient diagnosed with Barrett's esophagus per year). Diagnosis requires endoscopy and biopsy. In general, high-grade dysplasia and early stages of adenocarcinoma can be treated by endoscopic resection and/or endoscopic ablative therapy, whereas advanced stages (submucosal) are generally advised to undergo surgical treatment. Patients who undergo endoscopic resection and/or endoscopic ablative therapy might suffer from retrosternal discomfort and transient dysphagia, adverse effects that sometimes accompanies these procedures. One of the common post-procedural treatments is sucralfate 1 g 3 to 4 times daily for two weeks after the procedure. The rational for this treatment is to enhance the wound-healing process in the esophagus tissues and to coat the wounded tissues with a cytoprotective agent. As no clinical trials have been performed in order to prove the efficacy of sucralfate in the postprocedural treatment of Barrett's esophagus, this article summarizes the clinical experience accumulated from the treatment with sucralfate as a wound-healing enhancer. In addition, the article deals with the hypothesized mechanism of action of sucralfate and gives one option for compounding sucralfate oral viscous gel.

Related Keywords: Eyal Zur, BScPharm, RPh, MBA, Barrett esophagus, columnar epithelium, high-grade dysplasia, endoscopic therapy, adenocarcinoma risk factor, surgical wound healing, mucoadhesive sucralfate preparations, gastrointestinal reflux disease, GERD, viscous adhesive preparations, mucosal ulcers, mucosal erosion, formulations

Related Categories: FORMULATIONS, GASTROENTEROLOGY, WOUND CARE, UNITED STATES PHARMACOPEIA CONVENTIONS, DOSAGE FORMS/DRUG CARRIERS

Printer-Friendly Version




Download in electronic PDF format for $35

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Oral Viscous Sucralfate Gel for Post-procedural Treatment of Barrett's Esophagus Zur Eyal Sep/Oct 2019 376-381 Buy
Options in Wound Care Kincaid Michele R Mar/Apr 2002 92-95 Buy
Current Topical Treatments in Wound Healing - Part 1 Helmke Christopher D Jul/Aug 2004 269-274 Buy
Gastrointestinal Mucositis: Focus on the Treatment of the Effects of Chemotherapy and Radiotherapy on the Rectum Zur Eyal Mar/Apr 2012 117-124 Buy
Eosinophilic Esophagitis: Treatment with Oral Viscous Budesonide Zur Eyal Jul/Aug 2012 288-293 Buy
Basics of Compounding for Raynaud's Disease Glasnapp Andrew Jul/Aug 2003 288-291 Buy
The Treatment of Canine Atopic Disease Davidson Gigi S May/Jun 2002 210-215 Buy
Treating Canine Hepatic Disease Davidson Gigi S May/Jun 2003 188-191 Buy
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Stephenson Kenna, Neuenschwander Pierre F, Kurdowska Anna K Jan/Feb 2013 74-85 View Sample
Oral Mucositis: Etiology and Clinical and Pharmaceutical Management Zur Eyal Jan/Feb 2012 22-33 Buy